Drug Type Autologous CAR-T |
Synonyms NKG2D chimeric antigen receptor-T cells, KD 025, KD-025 |
Target |
Mechanism NKG2D antagonists(NKG2-D type II integral membrane protein antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | CN | - | |
NKG2DL Positive Solid Tumors | Phase 1 | CN | 17 May 2022 |
Not Applicable | Acute Myeloid Leukemia MICA/B | ULBPs-1 to 3 | 5 | (NKG2D-CAR T cells) | ddopxpzpwu(tmqtfvkxrs) = reduced expression uwyvxhzilm (toaatodtpn ) View more | Positive | 29 Aug 2020 | |
(NKG2D-CAR NKAE cells) | |||||||
Phase 2 | 54 | jgxxmuvtbh(cpaccamrtf) = Commonly reported AEs were URTI, AST/ALT elevations, fatigue, nausea and diarrhea. oeubhvosml (itkrhzevfg ) View more | Positive | 15 Jun 2019 | |||